GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

2 月 5 日，葛兰素史克（GSK）发布 2024 年财报， 全年营收 313.76 亿英镑（401.27 亿美元），同比增长 7%（按固定汇率计算，下同）。 研发投入 64.01 亿英镑 （81.86 亿美元），同比增长 5%。

Drugmaker GSK has been tapped as a potential target for activist investors, according to Bloomberg, which noted that shares had fallen roughly 19% since spinning off its consumer health business in ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

总的来说，GSK的肿瘤药产品销售实现翻倍，是制药行业在与癌症斗争中取得的阶段性胜利。未来，随着不断的技术革新和治疗方案的多样化，癌症的治愈率将有望逐渐提高，给无数患者和家庭带来希望与安宁。 返回搜狐，查看更多 ...

伦敦 - GSK（纽约证券交易所代码：GSK）旗下控股子公司ViiV Healthcare今日宣布，欧盟委员会已批准Vocabria和Rekambys长效注射方案用于治疗HIV-1感染的青少年。GSK市值710亿美元，根据InvestingPro的评估，其财务健康状况保持"优秀"，继续巩固其在制药行业的地位。这是首 ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...